ISRG · Intuitive Surgical Inc
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Oct 5, 2021; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| da Vinci 5 systems placed | 246 | Q2 2026 | — |
|
|
|||
| Da Vinci procedures growth | 15% | Q2 2026 | — |
|
|
|||
| da Vinci surgical system installed base | 11,710 | as of June 30, 2026 | — |
| Da Vinci surgical system installed base growth | 12% | as of June 30, 2026 | — |
| da Vinci surgical systems placed | 468 | Q2 2026 | — |
|
|
|||
| da Vinci surgical systems placed under operating lease arrangements | 254 | Q2 2026 | — |
|
|
|||
| da Vinci surgical systems placed under usage-based operating lease arrangements | 131 | Q2 2026 | — |
|
|
|||
| Ion endoluminal system installed base | 1,096 | as of June 30, 2026 | — |
| Ion endoluminal system installed base growth | 21% | as of June 30, 2026 | — |
| Ion endoluminal systems placed | 55 | Q2 2026 | — |
|
|
|||
| Ion procedures growth | 36% | Q2 2026 | — |
|
|
|||
| Worldwide procedures (da Vinci and Ion combined) growth | 16% | Q2 2026 | — |
| % Total recurring revenue | 84% | Full year 2025 | — |
| Average da Vinci system utilization | 4% | Q4 2025 | — |
| da Vinci Average Selling Price | $1.68M | Q4 2025 | — |
| da Vinci procedures | 725K | Q4 2025 | — |
| I&A revenue per procedure | $1.81K | Full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ISRG
this stock
Intuitive Surgical Inc
|
$141.76B | -30.3% | +20.5% | 46.1 | 1.9% |
|
BDX
Becton Dickinson & Co
|
$49.96B | — | +8.2% | — | 3.7% |
|
MDLN
Medline Inc.
|
$46.67B | -14.9% | +11.5% | — | 2.6% |
|
ALC
Alcon Inc
|
$35.97B | -5.8% | +10.5% | — | 2.8% |
|
RMD
Resmed Inc
|
$32.78B | -6.8% | +13.4% | 21.8 | 10.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Oct 5, 2021; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ISRG | +4.1% | +14.2% | -19.8% | +11.7% | -30.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +3.7% | +9.8% | -33.6% | +7.7% | -44.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.